- Home
- BRLT vs SABS Comparison
BRLT vs SABS Comparison
Compare BRLT & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRLT
- SABS
- Stock Information
- Founded
- BRLT 2005
- SABS 2014
- Country
- BRLT United States
- SABS United States
- Employees
- BRLT N/A
- SABS N/A
- Industry
- BRLT Consumer Specialties
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- BRLT Consumer Discretionary
- SABS Health Care
- Exchange
- BRLT Nasdaq
- SABS Nasdaq
- Market Cap
- BRLT 22.6M
- SABS 19.0M
- IPO Year
- BRLT 2021
- SABS N/A
- Fundamental
- Price
- BRLT $1.54
- SABS $1.20
- Analyst Decision
- BRLT Hold
- SABS Strong Buy
- Analyst Count
- BRLT 4
- SABS 5
- Target Price
- BRLT $2.20
- SABS $11.40
- AVG Volume (30 Days)
- BRLT 71.4K
- SABS 37.2K
- Earning Date
- BRLT 03-12-2025
- SABS 05-19-2025
- Dividend Yield
- BRLT N/A
- SABS N/A
- EPS Growth
- BRLT N/A
- SABS N/A
- EPS
- BRLT 0.03
- SABS N/A
- Revenue
- BRLT $422,161,000.00
- SABS $1,322,410.00
- Revenue This Year
- BRLT $2.43
- SABS N/A
- Revenue Next Year
- BRLT $10.40
- SABS $25.00
- P/E Ratio
- BRLT $49.87
- SABS N/A
- Revenue Growth
- BRLT N/A
- SABS N/A
- 52 Week Low
- BRLT $1.25
- SABS $1.11
- 52 Week High
- BRLT $3.02
- SABS $5.01
- Technical
- Relative Strength Index (RSI)
- BRLT 57.67
- SABS 33.63
- Support Level
- BRLT $1.54
- SABS $1.53
- Resistance Level
- BRLT $1.75
- SABS $1.80
- Average True Range (ATR)
- BRLT 0.13
- SABS 0.15
- MACD
- BRLT 0.03
- SABS 0.02
- Stochastic Oscillator
- BRLT 41.94
- SABS 0.00
About BRLT Brilliant Earth Group Inc.
Brilliant Earth Group Inc designs, procures and sells ethically-sourced diamonds, gemstones and jewelry online and through showrooms. Its sales consist of revenue from diamond, gemstone, and jewelry retail sales. The company sells its products in the U.S. and other international countries, of which a majority of revenue is derived from the U.S.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.